Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project

Orally administered direct-acting antivirals (DAAs) have dramatically changed the possibility of curing HCV (hepatitis C virus) infection, with the two principal HCV regimens based on the combination of glecaprevir + pibrentasvir (GLE-PIB) and sofosbuvir + velpatasvir (SOF-VEL). A combination of dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Borghi, Claudio, Ciancio, Alessia, Gentile, Ivan, Perrone Filardi, Pasquale, Pasqualetti, Patrizio, Brillanti, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737105/
https://www.ncbi.nlm.nih.gov/pubmed/36498521
http://dx.doi.org/10.3390/jcm11236946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737105/
https://www.ncbi.nlm.nih.gov/pubmed/36498521
http://dx.doi.org/10.3390/jcm11236946

Ejemplares similares